Business Description
Altimmune Inc
NAICS : 325412
SIC : 2834
ISIN : US02155H1014
Total Employee Number:
57Description
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.06 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.41 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.58 | |||||
Beneish M-Score | 16.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.1 | |||||
3-Year EPS without NRI Growth Rate | 17.9 | |||||
3-Year FCF Growth Rate | 16.9 | |||||
3-Year Book Growth Rate | -18.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.81 | |||||
9-Day RSI | 56.77 | |||||
14-Day RSI | 57.08 | |||||
3-1 Month Momentum % | 17.26 | |||||
6-1 Month Momentum % | -19.77 | |||||
12-1 Month Momentum % | -15.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 26.78 | |||||
Quick Ratio | 26.78 | |||||
Cash Ratio | 26.1 | |||||
Days Sales Outstanding | 17404.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -31.1 | |||||
Shareholder Yield % | -65.19 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -323306.45 | |||||
Net Margin % | -296000 | |||||
EBITDA Margin % | -284274.19 | |||||
FCF Margin % | -253576.92 | |||||
OCF Margin % | -253400 | |||||
ROE % | -34.49 | |||||
ROA % | -29.57 | |||||
ROIC % | -250.4 | |||||
3-Year ROIIC % | 49.49 | |||||
ROC (Joel Greenblatt) % | -34435.6 | |||||
ROCE % | -29.59 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.35 | |||||
Price-to-Tangible-Book | 1.35 | |||||
EV-to-EBIT | -3.96 | |||||
EV-to-EBITDA | -3.97 | |||||
EV-to-Forward-EBITDA | -2.55 | |||||
EV-to-Revenue | 11280.71 | |||||
EV-to-Forward-Revenue | 22625.59 | |||||
EV-to-FCF | -4.57 | |||||
| Price-to-Net-Current-Asset-Value | 2.27 | |||||
| Price-to-Net-Cash | 2.33 | |||||
Earnings Yield (Greenblatt) % | -25.25 | |||||
FCF Yield % | -11.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Altimmune Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.026 | ||
| EPS (TTM) (€) | -0.67 | ||
| Beta | 4.8761 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 1.54 | ||
| Volatility % | 85.67 | ||
| 14-Day RSI | 57.08 | ||
| 14-Day ATR (€) | 0.122494 | ||
| 20-Day SMA (€) | 2.7135 | ||
| 12-1 Month Momentum % | -15.71 | ||
| 52-Week Range (€) | 2.195 - 5.24 | ||
| Shares Outstanding (Mil) | 194.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Altimmune Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Altimmune Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-05 08:30 | In 176 days | ||
| Annual report for 2026 | 2027-03-05 | In 175 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-05 | In 175 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 57 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 56 days | ||
| General meeting for 2026 | 2026-09-25 08:30 | In 15 days | ||
| Wells Fargo 21(st) Annual Healthcare Conference | 2026-09-10 09:30 | 2.88 (+1.77%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 08:30 | 2.60 (+0.19%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 2.60 (+0.19%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 08:00 | 2.30 (-0.65%) |
Show
Entries
Altimmune Inc Frequently Asked Questions
What is Altimmune Inc(STU:3G0)'s stock price today?
The current price of STU:3G0 is €2.82. The 52 week high of STU:3G0 is €5.24 and 52 week low is €2.19.
When is next earnings date of Altimmune Inc(STU:3G0)?
The next earnings date of Altimmune Inc(STU:3G0) is 2026-11-06 Est..
Does Altimmune Inc(STU:3G0) pay dividends? If so, how much?
Altimmune Inc(STU:3G0) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers